arrow_back Back to App

Increasing Diversity in Clinical Trials and Health Data

This act aims to boost participation of diverse groups in clinical trials, especially for COVID-19. It will make remote trials easier and ensure that medicines and therapies are better suited for all citizens, regardless of background or status. Additionally, it will improve health data collection, aiding better public health planning.
Key points
Facilitating remote participation in clinical trials (e.g., via telemedicine), increasing accessibility for people from various regions and backgrounds.
Encouraging participation in trials from racial and ethnic minorities, the elderly, and low-income populations to make study results more representative.
Allowing free provision of digital devices (e.g., smartphones) for trial participation, reducing financial barriers for participants.
Improving demographic data collection for COVID-19 to better understand the disease's impact on different social groups and plan aid more effectively.
Simplifying rules for compensation in clinical trials to encourage more people to participate.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_2706
Sponsor: Sen. Menendez, Robert [D-NJ]
Process start date: 2021-08-10
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

DIVERSE Trials Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_2706.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-08-10.

What are the main provisions?

Key points include:

  • Facilitating remote participation in clinical trials (e.g., via telemedicine), increasing accessibility for people from various regions and backgrounds.
  • Encouraging participation in trials from racial and ethnic minorities, the elderly, and low-income populations to make study results more representative.
  • Allowing free provision of digital devices (e.g., smartphones) for trial participation, reducing financial barriers for participants.
  • Improving demographic data collection for COVID-19 to better understand the disease's impact on different social groups and plan aid more effectively.
  • Simplifying rules for compensation in clinical trials to encourage more people to participate.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Menendez, Robert [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health